PCRC_R0924

Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer.

Key Eligibility:

• Pathologically (histologically or cytologically) proven diagnosis of prostatic adenocarcinoma within 180 days of registration at moderate- to high-risk for recurrence

• Zubrod performance status 0-1

• Clinically negative lymph nodes as established by imaging (pelvic and/or abdominal CT or MR), (but not by nodal sampling, or dissection) within 90 days prior to registration
Phase III
NCT01368588
Cancer, All Other
Genitourinary
Benjamin Bridges , M.D.
RTOG (Radiation Therapy Oncology Group)
Scot Lary

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.